Skip to Content
Merck
  • Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom.

Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom.

Thrombosis and haemostasis (2014-07-11)
Wan Chen, Leng Chuan Goh, Tse Siang Kang, R Manjunatha Kini
ABSTRACT

Snake venoms are excellent sources of pharmacologically active proteins and peptides, and hence are potential sources of leads for drug developments. It has been previously established that krait (Bungarus genus) venoms contain mainly neurotoxins. A screening for anticoagulants showed that Bungarus fasciatus venom exhibits potent anticoagulant effect in standard clotting assays. Through sequential fractionation of the venom by size exclusion and high performance liquid chromatographies, coupled with functional screening for anticoagulant activities, we have isolated and purified two anticoagulant proteins, termed BF-AC1 (Bungarus fasciatusanticoagulant 1) and BF-AC2. They have potent inhibitory activities (IC50 of 10 nM) on the extrinsic tenase complex. Structurally, these proteins each has two subunits covalently held together by disulfide bond(s). The N-terminal sequences of the individual subunits of BF-AC1 and BF-AC2 showed that the larger subunit is homologous to phospholipase A2, while the smaller subunit is homologous to Kunitz type serine proteinase inhibitor. Functionally, in addition to their anticoagulant activity, these proteins showed presynaptic neurotoxic effects in both in vivo and ex vivo experiments. Thus, BF-AC1 and BF-AC2 are structurally and functionally similar to β-bungarotoxins, a class of neurotoxins. The enzymatic activity of phospholipase A2 subunit plays a significant role in the anticoagulant activities. This is the first report on the anticoagulant activity ofβ-bungarotoxins and these results expand on the existing catalogue of haemostatically active snake venom proteins.

MATERIALS
Product Number
Brand
Product Description

Supelco
Acrylamide, analytical standard
Sigma-Aldrich
Trizma® base, puriss. p.a., ≥99.7% (T)
Supelco
Trizma® base, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Tris(hydroxymethyl)aminomethane, ≥99.8%
Sigma-Aldrich
Tris(hydroxymethyl)aminomethane, JIS special grade, ≥99.0%
Sigma-Aldrich
Tris(hydroxymethyl)aminomethane, ≥99.8%
Sigma-Aldrich
Acrylamide, SAJ first grade, ≥98.0%
Sigma-Aldrich
Acrylamide, ≥99.9%
Sigma-Aldrich
Acrylamide, ≥98.0%
Sigma-Aldrich
Trizma® base, ≥99.0% (T)
Sigma-Aldrich
Trizma® base, BioUltra, for molecular biology, ≥99.8% (T)
Sigma-Aldrich
DL-Dithiothreitol solution, BioUltra, for molecular biology, ~1 M in H2O
Supelco
DL-Dithiothreitol solution, 1 M in H2O
Sigma-Aldrich
Tromethamine, meets USP testing specifications
Sigma-Aldrich
Trizma® base, ≥99.9% (titration), crystalline
Sigma-Aldrich
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline
Sigma-Aldrich
Trizma® base, BioPerformance Certified, meets EP, USP testing specifications, suitable for cell culture, ≥99.9% (titration)
Sigma-Aldrich
Acrylamide, for Northern and Southern blotting, powder blend
Sigma-Aldrich
Acrylamide, purum, ≥98.0% (GC)
Sigma-Aldrich
Acrylamide, for molecular biology, ≥99% (HPLC)
Sigma-Aldrich
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
Supelco
Tromethamine, pharmaceutical secondary standard, certified reference material
Sigma-Aldrich
Trizma® base, anhydrous, free-flowing, Redi-Dri, ≥99.9%
Trometamol, European Pharmacopoeia (EP) Reference Standard
USP
Tromethamine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acrylamide, suitable for electrophoresis, ≥99% (HPLC), powder
Sigma-Aldrich
Acrylamide, suitable for electrophoresis, ≥99%
Supelco
Acrylamide, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland